Peter Polack, MD
Cornea and External Diseases Specialist · Ocala, FLNPI 1821080771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Dompe US, Inc. at 31.1% of the total. 2025 is the largest year on record at $289, more than ten times the $23 reported in 2019.
Across 16 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$135
- Rxsight Inc$128
- Alcon$67
- Johnson & Johnson Surgical Vision, Inc.$26
- Harrow Eye, LLC$21
- Bausch & Lomb Americas Inc.$18
- plus $39 from 3 others
What the payments were for
- Food & beverage$41696%
- Education$184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 6 | $135 |
| Rxsight Inc | 1 | $128 |
| Alcon | 3 | $67 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $21 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Omeros Corporation | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cornea and external diseases specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 42 | $1,520,755 |
| XdemvyLotilaner | 35 | $68,836 |
| RestasisCyclosporine | 44 | $60,689 |
| XiidraLifitegrast | 27 | $32,043 |
| Prednisolone Acetate | 481 | $16,752 |
| LumiganBimatoprost | 25 | $9,089 |
| Cyclosporine | 14 | $7,936 |
| ValacyclovirValacyclovir Hcl | 109 | $6,172 |
| Fluorometholone | 66 | $5,635 |
| Latanoprost | 381 | $5,615 |
| Gatifloxacin | 61 | $4,148 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $3,864 |
| Ketorolac Tromethamine | 139 | $2,915 |
| Loteprednol Etabonate | 17 | $2,362 |
| Timolol Maleate | 102 | $2,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $135 | $1,520,75542 claims |
| Bausch & Lomb Americas Inc.Xiidra | $18 | $32,04327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Ocala
- Priya MathewsVenice$358K
- Alfonso SabaterMiami$40K
- Mark HerschelWinter Park$6K
- Leslie GarayOrlando$5K
- Ana Maria OlivaBrandon$5K
- Ansuya DeosaranBoynton Beach$3K
- Malka KirschenbaumBoynton Beach$3K
- Samantha HabhabJacksonville$3K
- Neha ShaikPalm Beach Gardens$2K
- Louis MichaelosLargo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.